Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects

This is an open-label, single sequence study that is being conducted to investigate the
potential drug-drug interaction (DDI) when GSK3640254 is co-administered with a cocktail of
cytochrome P450 (CYP) enzymes and transporter probe substrates in healthy participants. This
study will aid in understanding these interactions and resulting changes in exposure (if any)
when drugs that are metabolized via these pathways are given in combination with GSK3640254.
The study will consist of a Screening period and 3 sequential treatment regimens.
Participants will be administered a single dose of probe substrate drugs (caffeine 200
milligram (mg), metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg,
midazolam 5 mg, digoxin 0.25 mg and pravastatin 40 mg) on Day 1. Participants will then
receive GSK3640254 200 mg once daily on Days 11 to 20 followed by co-administration of probe
substrate drugs with GSK3640254 on Day 21.